LIVIVO - Search results -

Search results

Result 1 - 10 of total 38

Search options

Article: Increased lipocalin-2 expression in pulmonary inflammation and fibrosis.

Galaris, Apostolos / Fanidis, Dionysios / Tsitoura, Eliza / Kanellopoulou, Paraskevi / Barbayianni, Ilianna / Ntatsoulis, Konstantinos / Touloumi, Katerina / Gramenoudi, Sofia / Karampitsakos, Theodoros / Tzouvelekis, Argyrios / Antoniou, Katerina / Aidinis, Vassilis

Frontiers in medicine

2023 Volume 10, Page(s) 1195501

Abstract: Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent ... ...

Abstract	Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for disease initiation and perpetuation, via the secretion of soluble factors that amplify inflammation and lead to fibroblast activation and exuberant deposition of ECM components. Lipocalin-2 (LCN2) is a neutrophil gelatinase-associated lipocalin (NGAL) that has been suggested as a biomarker of kidney damage. LCN2 has been reported to modulate innate immunity, including the recruitment of neutrophils, and to protect against bacterial infections by sequestering iron. Methods: In silico Results and discussion: Increased
Language	English
Publishing date	2023-09-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2023.1195501
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis.

Barbayianni, Ilianna / Kanellopoulou, Paraskevi / Fanidis, Dionysios / Nastos, Dimitris / Ntouskou, Eleftheria-Dimitra / Galaris, Apostolos / Harokopos, Vaggelis / Hatzis, Pantelis / Tsitoura, Eliza / Homer, Robert / Kaminski, Naftali / Antoniou, Katerina M / Crestani, Bruno / Tzouvelekis, Argyrios / Aidinis, Vassilis

Nature communications

2023 Volume 14, Issue 1, Page(s) 5882

Abstract: The activation and accumulation of lung fibroblasts resulting in aberrant deposition of extracellular matrix components, is a pathogenic hallmark of Idiopathic Pulmonary Fibrosis, a lethal and incurable disease. In this report, increased expression of ... ...

Abstract	The activation and accumulation of lung fibroblasts resulting in aberrant deposition of extracellular matrix components, is a pathogenic hallmark of Idiopathic Pulmonary Fibrosis, a lethal and incurable disease. In this report, increased expression of TKS5, a scaffold protein essential for the formation of podosomes, was detected in the lung tissue of Idiopathic Pulmonary Fibrosis patients and bleomycin-treated mice. Τhe profibrotic milieu is found to induce TKS5 expression and the formation of prominent podosome rosettes in lung fibroblasts, that are retained ex vivo, culminating in increased extracellular matrix invasion. Tks5
MeSH term(s)	Animals ; Humans ; Mice ; Adaptor Proteins, Vesicular Transport ; Bleomycin ; Extracellular Matrix ; Fibroblasts ; Idiopathic Pulmonary Fibrosis/chemically induced ; Podosomes ; Proto-Oncogene Proteins pp60(c-src)/metabolism
Chemical Substances	Adaptor Proteins, Vesicular Transport ; Bleomycin (11056-06-7) ; Fish protein, mouse ; Proto-Oncogene Proteins pp60(c-src) (EC 2.7.10.2)
Language	English
Publishing date	2023-09-21
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-41614-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [COMMENT] Respiratory diseases in the era of COVID-19: Pearls and pitfalls.

Bolaki, Maria / Tsitoura, Eliza / Spandidos, Demetrios A / Symvoulakis, Emmanouil K / Antoniou, Katerina M

Experimental and therapeutic medicine

2020 Volume 20, Issue 2, Page(s) 691–693

Abstract: Coronavirus disease 2019, a respiratory tract infection that has evolved into a pandemic, is expected to affect patients with underlying respiratory disease in a greater number and greater severity than patients with other underlying disorders. Whether ... ...

Abstract	Coronavirus disease 2019, a respiratory tract infection that has evolved into a pandemic, is expected to affect patients with underlying respiratory disease in a greater number and greater severity than patients with other underlying disorders. Whether this is true is an interesting question. However, the challenge both for the doctors and patients is to keep the respiratory disease in remission and prevent any exacerbations. Proper recommendations have been proposed for a wide range of respiratory disorders including chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases, regarding the continuation or not of the treatment during this period and ways to maintain stability.
Keywords	covid19
Language	English
Publishing date	2020-05-20
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2020.8776
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).

Vasarmidi, Eirini / Tsitoura, Eliza / Spandidos, Demetrios A / Tzanakis, Nikolaos / Antoniou, Katerina M

Experimental and therapeutic medicine

2020 Volume 20, Issue 3, Page(s) 2557–2560

Abstract: The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While ... ...

Abstract	The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients.
Keywords	covid19
Language	English
Publishing date	2020-07-09
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2020.8980
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care.

Antoniou, Katerina M / Tsitoura, Eliza / Vasarmidi, Eirini / Symvoulakis, Emmanouil K / Aidinis, Vassilis / Tzilas, Vassilis / Tzouvelekis, Argyris / Bouros, Demosthenes

Current opinion in pharmacology

2021 Volume 57, Page(s) 71–80

Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic chronic lung disease affecting predominantly older adults, with a history of smoking. The current model of disease natural course is that recurrent injury of the alveolar ... ...

Abstract	Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic chronic lung disease affecting predominantly older adults, with a history of smoking. The current model of disease natural course is that recurrent injury of the alveolar epithelium in the context of advanced aging/cellular senescence is followed by defective re-epithelialization and scar tissue formation. Currently, two drugs, nintedanib and pirfenidone, that modify disease progression have been approved worldwide for the treatment of IPF. However, despite treatment, patients with IPF are not cured, and eventually, disease advances in most treated patients. Enhancing biogenomic and metabolic research output, its translation into clinical precision and optimal service delivery through patient-centeredness are key elements to support effective IPF care. In this review, we summarize therapeutic options currently investigated for IPF based on the major pathogenetic pathways and molecular targets that drive pulmonary fibrosis.
MeSH term(s)	Aged ; Fibrosis ; Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Patient-Centered Care ; Precision Medicine ; Translational Medical Research
Language	English
Publishing date	2021-02-06
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2037057-X
ISSN	1471-4973 ; 1471-4892
ISSN (online)	1471-4973
ISSN	1471-4892
DOI	10.1016/j.coph.2020.12.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5608: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mesenchymal stem cell treatment for IPF-time for phase 2 trials?

Antoniou, Katerina M / Karagiannis, Konstantinos / Tsitoura, Eliza / Tzanakis, Nikos

The Lancet. Respiratory medicine

2017 Volume 5, Issue 6, Page(s) 472–473

MeSH term(s)	Clinical Trials, Phase II as Topic ; Humans ; Idiopathic Pulmonary Fibrosis/therapy ; Mesenchymal Stem Cell Transplantation
Language	English
Publishing date	2017-05-26
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2686754-0
ISSN	2213-2619 ; 2213-2600
ISSN (online)	2213-2619
ISSN	2213-2600
DOI	10.1016/S2213-2600(17)30180-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7041: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.

Ntatsoulis, Konstantinos / Karampitsakos, Theodoros / Tsitoura, Eliza / Stylianaki, Elli-Anna / Matralis, Alexios N / Tzouvelekis, Argyrios / Antoniou, Katerina / Aidinis, Vassilis

Frontiers in immunology

2021 Volume 12, Page(s) 687397

Abstract: Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis ... ...

Abstract	Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; COVID-19/blood ; COVID-19/pathology ; Dexamethasone/therapeutic use ; Humans ; Lung/pathology ; Lysophospholipids/metabolism ; Phosphoric Diester Hydrolases/blood ; Phosphoric Diester Hydrolases/metabolism ; Pulmonary Fibrosis/blood ; Pulmonary Fibrosis/pathology ; Respiratory Distress Syndrome/blood ; Respiratory Distress Syndrome/pathology ; SARS-CoV-2 ; Signal Transduction/immunology
Chemical Substances	Anti-Inflammatory Agents ; Lysophospholipids ; Dexamethasone (7S5I7G3JQL) ; Phosphoric Diester Hydrolases (EC 3.1.4.-) ; alkylglycerophosphoethanolamine phosphodiesterase (EC 3.1.4.39) ; lysophosphatidic acid (PG6M3969SG)
Language	English
Publishing date	2021-10-04
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.687397
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy.

Kachris, Stefanos / Papadaki, Chara / Rounis, Konstantinos / Tsitoura, Eliza / Kokkinaki, Chrysanthi / Nikolaou, Christoforos / Sourvinos, George / Mavroudis, Dimitrios

Cancer management and research

2021 Volume 13, Page(s) 8257–8271

Abstract: Introduction: Disease recurrence is a major concern in patients with localized prostate cancer (PCa) following treatment with radiotherapy (RT), and few studies have evaluated the clinical relevance of microRNAs (miRNAs) prior and post-RT.: Purpose: ... ...

Abstract	Introduction: Disease recurrence is a major concern in patients with localized prostate cancer (PCa) following treatment with radiotherapy (RT), and few studies have evaluated the clinical relevance of microRNAs (miRNAs) prior and post-RT. Purpose: We aimed to investigate the significance of miRNAs in the outcomes of prostate cancer patients undergoing radiotherapy and to identify the related pathways through bioinformatics analysis. Materials and methods: The expression levels of miR-21, miR-106b, miR-141 and miR-375 involved in the response to radiotherapy were assessed by RT-qPCR in the serum of PCa patients (n=56) prior- and post-RT. Results: Low expression levels of miR-106b prior-RT were associated with extracapsular extension and seminal vesicles invasion by the tumor (p=0.031 and 0.044, respectively). In the high-risk subgroup (n=47), post-RT expression levels of miR-21 were higher in patients with biochemical relapse (BR) compared to non-relapse (p=0.043). Also, in the salvage treatment subgroup (post-operative BR; n=20), post-RT expression levels of miR-21 and miR-106b were higher in patients with BR compared to non-relapse (p=0.043 and p=0.032, respectively). In the whole group of patients, high expression levels of miR-21 prior-RT and of miR-106b post-RT were associated with significantly shorter overall survival (OS; p=0.049 and p=0.050, respectively). No associations were observed among miR-141 and miR-375 expression levels with clinicopathological features or treatment outcome. Bioinformatics analysis revealed significant enrichment in DNA damage response pathways. Conclusion: Circulating miRNAs prior or post-RT may hold prognostic implications in patients with PCa.
Language	English
Publishing date	2021-11-02
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2508013-1
ISSN	1179-1322
ISSN	1179-1322
DOI	10.2147/CMAR.S325246
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver.

Tsitoura, Eliza / Bibaki, Eleni / Bolaki, Maria / Vasarmidi, Eirini / Trachalaki, Athina / Symvoulakis, Emmanouil K / Spandidos, Demetrios A / Antoniou, Katerina M

Experimental and therapeutic medicine

2020 Volume 20, Issue 1, Page(s) 147–150

Abstract: SARS-coronavirus-2 (SARS-CoV-2), the etiologic agent of the new lung disease COVID-19 is closely related to SARS-CoV, and together with MERS-CoV are three new human coronaviruses that emerged in the last 20 years. The COVID-19 outbreak is a rapidly ... ...

Abstract	SARS-coronavirus-2 (SARS-CoV-2), the etiologic agent of the new lung disease COVID-19 is closely related to SARS-CoV, and together with MERS-CoV are three new human coronaviruses that emerged in the last 20 years. The COVID-19 outbreak is a rapidly evolving situation with higher transmissibility and infectivity compared with SARS and MERS. Clinical presentations range from asymptomatic or mild symptoms to severe illness. The prevalent cause of mortality is pneumonia that progresses to ARDS. The ongoing pandemic has already resulted in more than 135,000 deaths and an unprecedented burden on national health systems worldwide. Pending the availability of a vaccine, there is a critical need to identify effective treatments and a number of clinical trials have been implemented worldwide. Trials are based on repurposed drugs that are already approved for other infections, have acceptable safety profiles or have performed well in animal studies against the other two deadly coronaviruses. Supportive care remains the mainstay of therapy at present, as it is still unclear how well these data can be extrapolated to SARS-CoV-2. Most of those emerging re-introduced drugs are administered to patients in the context of clinical trials. In this review, we summarize the strategies currently employed in the treatment of COVID-19.
Keywords	covid19
Language	English
Publishing date	2020-04-28
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2020.8692
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Influence of reaming intramedullary nailing on MSC population after surgical treatment of patients with long bone fracture.

Sperelakis, Ioannis / Tsitoura, Eliza / Koutoulaki, Chara / Mastrodimou, Semeli / Tosounidis, Theodoros H / Spandidos, Demetrios A / Antoniou, Katerina M / Kontakis, George

Molecular medicine reports

2020 Volume 22, Issue 3, Page(s) 2521–2527

Abstract: Reamed intramedullary nailing (RIN) is a surgical method of choice for treatment of diaphyseal fractures. This procedure affects the biological environment of bone tissue locally and systemically. This study investigated the influence of RIN on ... ...

Abstract	Reamed intramedullary nailing (RIN) is a surgical method of choice for treatment of diaphyseal fractures. This procedure affects the biological environment of bone tissue locally and systemically. This study investigated the influence of RIN on mesenchymal stem cells (MSCs) in patients with long bone fractures. The axis of C-X-C motif chemokine receptor 4 (CXCR4)/stromal cell-derived factor 1 (SDF‑1) was selected since it is considered as major pathway for MSC homing and migration. Iliac crest bone marrow (IC‑BM) samples and blood samples were collected at two different time points. One sample was collected before the RIN (BN) and the other immediately after RIN (AN). BM‑MSCs were cultured and RT‑qPCR was performed for CXCR4 mRNA levels and ELISA for the SDF‑1 sera levels. The experimental study revealed that there was a correlation between the increase of SDF‑1 levels in peripheral blood and a decrease in the levels of CXCR4 in MSCs in the IC‑BM following RIN. The levels of SDF‑1 showed a significant increase in the sera of patients after RIN. In conclusion, the present study is the first providing evidence of the effects of RIN on MSC population via the CXCR4/SDF‑1 axis. The levels of serum SDF‑1 factor were elevated after RIN while increased levels of SDF‑1 in peripheral blood were inversely correlated with the mRNA levels of CXCR4 on BM‑MSCs after RIN. Therefore, this study contributes to enlighten the systematic effects of RIN on the population of MSCs at a cellular level.
MeSH term(s)	Adult ; Cells, Cultured ; Chemokine CXCL12/blood ; Female ; Fracture Fixation, Intramedullary/instrumentation ; Fractures, Bone/metabolism ; Fractures, Bone/surgery ; Humans ; Male ; Mesenchymal Stem Cells/cytology ; Mesenchymal Stem Cells/metabolism ; Middle Aged ; Receptors, CXCR4/genetics ; Up-Regulation ; Young Adult
Chemical Substances	CXCL12 protein, human ; CXCR4 protein, human ; Chemokine CXCL12 ; Receptors, CXCR4
Language	English
Publishing date	2020-07-09
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2469505-1
ISSN	1791-3004 ; 1791-2997
ISSN (online)	1791-3004
ISSN	1791-2997
DOI	10.3892/mmr.2020.11320
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito